Is LSTA or ERNA more profitable?

Lisata Therapeutics' return on equity of -103.54% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% Ernexa Therapeutics N/A -263.74% -151.16%

Does the media refer more to LSTA or ERNA?

In the previous week, Lisata Therapeutics had 1 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 6 mentions for Lisata Therapeutics and 5 mentions for Ernexa Therapeutics. Lisata Therapeutics' average media sentiment score of 0.81 beat Ernexa Therapeutics' score of 0.57 indicating that Lisata Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lisata Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend APLM or ERNA?

Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 354.27%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, APLM or ERNA?

Apollomics has higher revenue and earnings than Ernexa Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 3.54 -$10.94M N/A N/A Ernexa Therapeutics N/A N/A -$14.08M -$26.20 N/A

Is APLM or ERNA more profitable?

Apollomics' return on equity of 0.00% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Ernexa Therapeutics N/A -263.74% -151.16%

Do analysts prefer CPHI or ERNA?

Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 354.27%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ERNA or EVAX more profitable?

Evaxion A/S's return on equity of -73.56% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -263.74% -151.16% Evaxion A/S N/A -73.56% -37.45%

Does the media refer more to ERNA or EVAX?

In the previous week, Ernexa Therapeutics had 2 more articles in the media than Evaxion A/S. MarketBeat recorded 5 mentions for Ernexa Therapeutics and 3 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 0.63 beat Ernexa Therapeutics' score of 0.57 indicating that Evaxion A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate QUCY or ERNA?

Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 354.27%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ernexa Therapeutics is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is QUCY or ERNA more profitable?

Mainz Biomed's return on equity of 0.00% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Ernexa Therapeutics N/A -263.74% -151.16%

Does the media favor QUCY or ERNA?

In the previous week, Mainz Biomed and Mainz Biomed both had 5 articles in the media. Mainz Biomed's average media sentiment score of 0.57 equaled Ernexa Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ernexa Therapeutics (ERNA) Competitors

$6.60 +0.45 (+7.38%)

As of 10:06 AM Eastern

Compare

ERNA vs. LSTA, APLM, CPHI, EVAX, and QUCY

Should you buy Ernexa Therapeutics stock or one of its competitors? MarketBeat compares Ernexa Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ernexa Therapeutics include Lisata Therapeutics (LSTA), Apollomics (APLM), China Pharma (CPHI), Evaxion A/S (EVAX), and Mainz Biomed (QUCY). These companies are all part of the "pharmaceutical products" industry.

How does Ernexa Therapeutics compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Lisata Therapeutics had 1 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 6 mentions for Lisata Therapeutics and 5 mentions for Ernexa Therapeutics. Lisata Therapeutics' average media sentiment score of 0.81 beat Ernexa Therapeutics' score of 0.57 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lisata Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lisata Therapeutics' return on equity of -103.54% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

Lisata Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.49, indicating that its stock price is 149% more volatile than the broader market.

Ernexa Therapeutics has lower revenue, but higher earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	186.46	-$16.59M	-$1.86	N/A
Ernexa Therapeutics	N/A	N/A	-$14.08M	-$26.20	N/A

Lisata Therapeutics presently has a consensus price target of $15.00, indicating a potential upside of 330.91%. Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 354.27%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lisata Therapeutics and Ernexa Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLM) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

In the previous week, Ernexa Therapeutics had 3 more articles in the media than Apollomics. MarketBeat recorded 5 mentions for Ernexa Therapeutics and 2 mentions for Apollomics. Apollomics' average media sentiment score of 1.44 beat Ernexa Therapeutics' score of 0.57 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Positive
Ernexa Therapeutics	Positive

Apollomics' return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Ernexa Therapeutics	N/A	-263.74%	-151.16%

Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 354.27%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Apollomics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.49, indicating that its share price is 149% more volatile than the broader market.

19.1% of Apollomics shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Apollomics has higher revenue and earnings than Ernexa Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	3.54	-$10.94M	N/A	N/A
Ernexa Therapeutics	N/A	N/A	-$14.08M	-$26.20	N/A

Summary

Ernexa Therapeutics beats Apollomics on 7 of the 12 factors compared between the two stocks.

How does Ernexa Therapeutics compare to China Pharma?

China Pharma (NYSE:CPHI) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 354.27%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ernexa Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

China Pharma has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.49, meaning that its stock price is 149% more volatile than the broader market.

In the previous week, Ernexa Therapeutics had 5 more articles in the media than China Pharma. MarketBeat recorded 5 mentions for Ernexa Therapeutics and 0 mentions for China Pharma. Ernexa Therapeutics' average media sentiment score of 0.57 beat China Pharma's score of 0.32 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
China Pharma	Neutral
Ernexa Therapeutics	Positive

70.6% of Ernexa Therapeutics shares are held by institutional investors. 6.4% of China Pharma shares are held by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

China Pharma has higher revenue and earnings than Ernexa Therapeutics. China Pharma is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	7.96	-$3.08M	-$0.55	N/A
Ernexa Therapeutics	N/A	N/A	-$14.08M	-$26.20	N/A

Summary

Ernexa Therapeutics beats China Pharma on 9 of the 15 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Evaxion A/S?

Ernexa Therapeutics (NASDAQ:ERNA) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Evaxion A/S's return on equity of -73.56% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-263.74%	-151.16%
Evaxion A/S	N/A	-73.56%	-37.45%

Ernexa Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 354.27%. Evaxion A/S has a consensus target price of $11.00, indicating a potential upside of 189.40%. Given Ernexa Therapeutics' higher possible upside, research analysts plainly believe Ernexa Therapeutics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Ernexa Therapeutics has a beta of 2.49, meaning that its stock price is 149% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

In the previous week, Ernexa Therapeutics had 2 more articles in the media than Evaxion A/S. MarketBeat recorded 5 mentions for Ernexa Therapeutics and 3 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 0.63 beat Ernexa Therapeutics' score of 0.57 indicating that Evaxion A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 41.6% of Evaxion A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Evaxion A/S has higher revenue and earnings than Ernexa Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	N/A	N/A	-$14.08M	-$26.20	N/A
Evaxion A/S	$7.53M	4.21	-$7.71M	-$1.47	N/A

Summary

Evaxion A/S beats Ernexa Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Mainz Biomed?

Mainz Biomed (NASDAQ:QUCY) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

In the previous week, Mainz Biomed and Mainz Biomed both had 5 articles in the media. Mainz Biomed's average media sentiment score of 0.57 equaled Ernexa Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ernexa Therapeutics has lower revenue, but higher earnings than Mainz Biomed. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$537.08K	52.82	-$16.21M	-$47.60	N/A
Ernexa Therapeutics	N/A	N/A	-$14.08M	-$26.20	N/A

Mainz Biomed has a beta of 2.22, indicating that its stock price is 122% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.49, indicating that its stock price is 149% more volatile than the broader market.

70.6% of Ernexa Therapeutics shares are held by institutional investors. 3.1% of Mainz Biomed shares are held by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Mainz Biomed's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Ernexa Therapeutics	N/A	-263.74%	-151.16%

Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 354.27%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ernexa Therapeutics is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Ernexa Therapeutics beats Mainz Biomed on 7 of the 12 factors compared between the two stocks.

Get Ernexa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERNA vs. The Competition

Export

Metric	Ernexa Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.63M	$2.99B	$6.49B	$12.31B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-0.25	18.81	24.05	24.76
Price / Sales	N/A	468.63	542.61	168.32
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	0.86	4.01	10.69	6.90
Net Income	-$14.08M	$75.79M	$3.57B	$337.45M
7 Day Performance	-10.64%	2.78%	1.56%	2.84%
1 Month Performance	-51.55%	0.52%	2.49%	4.78%
1 Year Performance	-88.46%	24.68%	26.51%	33.08%

Ernexa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERNA Ernexa Therapeutics	3.6766 of 5 stars	$6.60 +7.4%	$30.00 +354.3%	-89.3%	$7.63M	N/A	N/A	10	Gap Up
LSTA Lisata Therapeutics	2.2764 of 5 stars	$3.61 +4.3%	$15.00 +315.5%	+42.3%	$31.51M	$170K	N/A	30	High Trading Volume
APLM Apollomics	1.66 of 5 stars	$13.82 -3.3%	N/A	+114.7%	$31.40M	$8.50M	N/A	45	Positive News Short Interest Decrease Gap Up
CPHI China Pharma	N/A	$0.77 +7.1%	N/A	-56.2%	$31.04M	$3.99M	N/A	250	Gap Up
EVAX Evaxion A/S	3.2972 of 5 stars	$3.79 +4.4%	$11.00 +190.2%	+31.4%	$30.27M	$7.53M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERNA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. LSTA, APLM, CPHI, EVAX, and QUCY

How does Ernexa Therapeutics compare to Lisata Therapeutics?

Summary

How does Ernexa Therapeutics compare to Apollomics?

Summary

How does Ernexa Therapeutics compare to China Pharma?

Summary

How does Ernexa Therapeutics compare to Evaxion A/S?

Summary

How does Ernexa Therapeutics compare to Mainz Biomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. LSTA, APLM, CPHI, EVAX, and QUCY

How does Ernexa Therapeutics compare to Lisata Therapeutics?

Does the media refer more to LSTA or ERNA?

Do institutionals and insiders believe in LSTA or ERNA?

Is LSTA or ERNA more profitable?

Which has more risk & volatility, LSTA or ERNA?

Which has preferable earnings and valuation, LSTA or ERNA?

Do analysts recommend LSTA or ERNA?

Summary

How does Ernexa Therapeutics compare to Apollomics?

Does the media refer more to APLM or ERNA?

Is APLM or ERNA more profitable?

Do analysts recommend APLM or ERNA?

Which has more volatility & risk, APLM or ERNA?

Do insiders and institutionals believe in APLM or ERNA?

Which has stronger valuation and earnings, APLM or ERNA?

Summary

How does Ernexa Therapeutics compare to China Pharma?

Do analysts prefer CPHI or ERNA?

Is CPHI or ERNA more profitable?

Which has more risk & volatility, CPHI or ERNA?

Does the media refer more to CPHI or ERNA?

Do insiders and institutionals have more ownership in CPHI or ERNA?

Which has stronger valuation & earnings, CPHI or ERNA?

Summary

How does Ernexa Therapeutics compare to Evaxion A/S?

Is ERNA or EVAX more profitable?

Do analysts rate ERNA or EVAX?

Which has more risk & volatility, ERNA or EVAX?

Does the media refer more to ERNA or EVAX?

Do institutionals & insiders hold more shares of ERNA or EVAX?

Which has stronger earnings & valuation, ERNA or EVAX?

Summary

How does Ernexa Therapeutics compare to Mainz Biomed?

Does the media favor QUCY or ERNA?

Which has preferable valuation and earnings, QUCY or ERNA?

Which has more risk and volatility, QUCY or ERNA?

Do insiders and institutionals believe in QUCY or ERNA?

Is QUCY or ERNA more profitable?

Do analysts rate QUCY or ERNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools